At the University of Nebraska Medical Center, HIV care providers scrambled to set up new systems in hopes of maintaining retention in care and viral suppression among as many patients as possible.
“Telling them now that ‘the government is saying I need to decrease your opioids. ... Sorry you’re going to suffer,’ was just not satisfying to me as a physician,” says Maile Young Karris, M.D.
A recent expert debate explored the pros and cons of prescribing the antibiotic as a preventive measure for a subset of people at especially high risk for sexually transmitted infections.
IDWeek 2020 provided a perfect opportunity to better understand the modern-day impact of histoplasmosis among Americans living with HIV—and to bone up on the basics.
Taken together, these studies appear to confirm that weight gain is a class effect of INSTIs, albeit with potential differences between individual drugs—and much left to be learned about the health impact.
The findings add to a growing body of research showing that it’s other co-morbidities, not HIV, that lead to worse health outcomes from COVID-19—at least among individuals who are on stable antiretroviral therapy.
Amidst uncertainty regarding the safety of some integrase inhibitors during pregnancy, a study shows that an older integrase inhibitor may be a good option for those with HIV who intend to give birth.
A series of studies aim to determine whether test-and-treat strategies can be implemented for people with hepatitis C, much like programs for people living with HIV.
With several new regimens nearing late-stage trials, a new generation of HIV antiretrovirals may soon be entering the marketplace.
2017 may be winding down, but even as the year wanes, we’ve seen significant new HIV research featured in major scientific conferences in the U.S. and Europe. IDWeek, most recently held in San Diego in early October 2017, is an annual infectious disease...